Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5258305 | 0.70 | MAPT (0.36) | CHRM2CHRM1 | |
| SCHEMBL5258311 | 0.70 | MAPT (0.36) | CHRM2CHRM1 | |
| SCHEMBL5257624 | 0.68 | CHRM2 (0.33) | CHRM2CHRM1 | |
| SCHEMBL5257617 | 0.68 | CHRM2 (0.33) | CHRM2CHRM1 | |
| SCHEMBL5260866 | 0.68 | CHRM2 (0.31) | CHRM2CHRM1 | |
| SCHEMBL5260871 | 0.68 | CHRM2 (0.31) | CHRM2CHRM1 | |
| SCHEMBL5259924 | 0.68 | CHRM2 (0.32) | CHRM2CHRM1 | |
| SCHEMBL5259921 | 0.68 | CHRM2 (0.32) | CHRM2CHRM1 | |
| SCHEMBL5256711 | 0.66 | CHRM2 (0.31) | CHRM2CHRM1 | |
| SCHEMBL5256713 | 0.66 | CHRM2 (0.31) | CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288549-B2 | Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | AVENTIS PHARMA S.A. (FR) | 2007-10-30 | — | — | US | disclosed |
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | ENTASIS THERAPEUTICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | FDPS, MRPL21, DHPS | CHRM2 4602/4885CHRM1 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.